secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268135
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity
--------------------------------------------------------------------------------

- Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.
- Cue Biopharma receives $15M upfront ($10M in Q4 2025, $5M in Nov 2026) and 40% equity stake in ImmunoScape.
- Cue Biopharma eligible for high-single-digit royalties on net sales of any products developed.
- IND-enabling studies on track for 2027 submission; preclinical data shown in pancreatic and ovarian cancer models.
- Cue Biopharma to focus on autoimmune disease programs while oncology development advances with ImmunoScape.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525268135/0001193125-25-268135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525268135/cue-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer